Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neuroectodermal Tumors × Vorinostat × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 26 Lymphoma 23 Precursor Cell Lymphoblastic Leukemia-Lymphoma 22 Multiple Myeloma 20 Lymphoma, Large B-Cell, Diffuse 20 Carcinoma, Non-Small-Cell Lung 18 Breast Neoplasms 18 Lymphoma, Non-Hodgkin 16 Lymphoma, Follicular 14 Hodgkin Disease 14 Lymphoma, Mantle-Cell 13 Lymphoma, T-Cell, Cutaneous 12 Leukemia, Lymphocytic, Chronic, B-Cell 11 Glioblastoma 11 Brain Neoplasms 11 Recurrence 10 Neuroblastoma 10 Myelodysplastic Syndromes 10 Mycosis Fungoides 10 Lymphoma, B-Cell, Marginal Zone 10 Burkitt Lymphoma 10 Congenital Abnormalities 9 Sezary Syndrome 8 Neoplasms 8 Leukemia 8 Prostatic Neoplasms 7 Neoplasms, Plasma Cell 7 Lymphoma, Large-Cell, Anaplastic 7 Lung Neoplasms 7 Leukemia, Myelomonocytic, Chronic 7

Interventions

Temozolomide 2 vorasidenib 1 repotrectinib 1 pralsetinib 1 pembrolizumab 1 pamiparib 1 lutetium Lu 177 dotatate 1 copper dotatate CU-64 1 cixutumumab 1 Vorinostat 1 Vincristine 1 Valproic Acid 1 Thiotepa 1 Sunitinib 1 Radiotherapy 1 Radiation 1 Peripheral Blood Stem Cell Transplantation 1 Oncolytic Virotherapy 1 ONC206 1 Melphalan 1 Maintenance Chemotherapy 1 Lutetium-177 1 Lutetium 1 Lomustine 1 Interleukin-12 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Etoposide 1 Erlotinib Hydrochloride 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03561259 2023-02-16

OPTIMUM

Jubilant DraxImage Inc.

Phase 2 Unknown

Neoplasms, Neuroblastoma, Neuroectodermal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡